Thymosin Alpha-1 in Combination with Pegylated Interferon and Ribavirin in Chronic Hepatitis C Patients Who have Failed to Prior Pegylated Interferon and Ribavirin Treatment.
- Author:
Yang Hyun BAEK
1
;
Sung Wook LEE
;
Hyun Seung YOO
;
Hyun Ah YOON
;
Ja Won KIM
;
Young Hoon KIM
;
Ha Youn KIM
;
Sang Young HAN
Author Information
1. Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea. syhan@dau.ac.kr
- Publication Type:Case Report
- Keywords:
Chronic hepatitis C;
Nonrespondents;
Peginterferon alpha-2a;
Ribavirin;
Thymosin alpha 1 Introduction
- MeSH:
Data Collection;
Genotype;
Hepatitis C, Chronic*;
Hepatitis, Chronic*;
Humans;
Interferons*;
Retreatment;
Ribavirin*;
Thymosin*;
Viral Load
- From:Gut and Liver
2007;1(1):87-89
- CountryRepublic of Korea
- Language:English
-
Abstract:
Combination therapy with inteferon-alpha and ribavirin is an approved therapy for patients with chronic hepatitis C. However, even with the use of pegylated interferon, response rates are still poor in many difficult-to-treat groups, especially with genotype 1 and high viral loads. Retreatment of these patients remains challenging. Newer combinations are being investigated to optimize chances of attaining a sustained response in these groups. Thymosin alpha 1 is a polypeptide with immunomodulatory properties that has been suggested to increase response rates in patients with chronic hepatitis C. Herein, we describe two cases of retreatment patients with chronic hepatitis C who have failed prior pegylated interferon and ribavirin therapy. They received triple combination therapies of thymosin alpha 1, pegylated interferon and ribavirin and achieved sustained virological responses. These cases support that thymosin-alpha 1 may increase the efficacy of pegylated interferon plus ribavirin in the treatment of non-responders to previous combination therapy.
